MD (Pediatrix Medical Group, Inc.)

Insider Trading Activity

Every open-market purchase and sale reported by MD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
9
code S
Reporting Insiders
25
current holders
MD — Recent Form 4 Transactions (latest 2026-06-24)
FiledInsiderRole TypeSharesValue
2026-06-24 David Haddock EVP, GC & Corp Sec A
2026-06-10 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec G
2026-06-03 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec F
2026-06-03 Kasandra H Rossi EVP, CFO and Treasurer MIXED
2026-06-03 MARK S ORDAN Chief Executive Officer MIXED
2026-06-03 Don Gregory Neeb EVP, Chief Invest & Strategy MIXED
2026-05-14 Shirley A Weis Director Sell
2026-05-14 Thomas McEachin Director G
2026-05-13 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec G
2026-05-11 GUY P SANSONE Director A
2026-05-11 Shirley A Weis Director A
2026-05-11 John M. Jr. Starcher Director A
2026-05-11 Sylvia Jean Young Director A
2026-05-11 Thomas McEachin Director A
2026-05-11 Michael A. Rucker Director A
2026-05-11 Kurt Douglas Newman Director A
2026-05-11 Laura A Linynsky Director A
2026-03-03 Kasandra H Rossi EVP, CFO and Treasurer F
2026-03-03 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec MIXED
2025-12-17 MARK S ORDAN Chief Executive Officer Sell
2025-11-19 Michael A. Rucker Director Sell
2025-11-10 Laura A Linynsky Director Sell
2025-08-21 Thomas McEachin Director G
2025-08-05 Kurt Douglas Newman Director A
2025-08-05 Don Gregory Neeb EVP, Chief Invest & Strategy A
2025-06-12 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec G
2025-06-03 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec MIXED
2025-06-03 MARK S ORDAN Chief Executive Officer A
2025-06-03 Kasandra H Rossi EVP, CFO and Treasurer MIXED
2025-05-27 Shirley A Weis Director G
2025-05-12 Sylvia Jean Young Director A
2025-05-12 Thomas McEachin Director A
2025-05-12 Michael A. Rucker Director A
2025-05-12 John M. Jr. Starcher Director A
2025-05-12 GUY P SANSONE Director A
2025-05-12 Shirley A Weis Director A
2025-05-12 MARK S ORDAN Chief Executive Officer F
2025-05-12 Laura A Linynsky Director A
2025-03-07 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec G
2025-03-04 Kasandra H Rossi EVP, CFO and Treasurer F
2025-03-04 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec F
2025-02-26 Shirley A Weis Director G
2025-01-14 MARK S ORDAN Chief Executive Officer A
2024-12-03 Kasandra H Rossi EVP, CFO and Treasurer A
2024-11-14 MARK S ORDAN Director Sell
2024-11-12 Mary Ann E Moore EVP, GC, Chief Admin Off & Sec Sell
2024-09-03 James D Swift Chief Executive Officer Sell
2024-08-29 Laura A Linynsky Director Sell
2024-08-13 C Marc Richards EVP, Chief Financial Officer Sell
2024-06-04 James D Swift Chief Executive Officer A
MD — Current Insider Holders
InsiderRole Shares HeldValue
Director 748,890
Director 605,005
President 414,687
Chief Executive Officer 410,884
EVP, Chief Financial Officer 192,785
EVP, GC, Chief Admin Off & Sec 189,890
EVP, General Counsel and Secy 189,440
Chief Executive Officer 170,001
EVP, Chief Invest & Strategy 145,234
EVP, Chief Operating Officer 143,055
Director 129,198
Chief Operating Officer 123,032
EVP, Natl & Market Operations 118,094
Pres., PDX & OBX Medical Group 109,457
President, Eastern Division 105,932
EVP, CFO and Treasurer 105,100
Chief Financial Officer 100,590
Principal Accounting Officer 96,666
Director 86,944
SVP, General Counsel and Secy. 86,594
Former Chief Financial Officer 78,027
Director 73,269
Director 73,260
EVP Chf Strategy & Growth Offi 71,954
Director 66,297
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the MD quote page; the site-wide leaderboard is on the insider transactions hub.